Publication Date January 15, 2021 If health and risk communication information and approaches remain static and are not updated to reflect the changing concerns, questions, and suggestions from communities, they will not remain relevant or trusted by people and the epidemic response will fail. This update to the risk communication and community engagement (RCCE) strategy for COVID-19 in Africa first set out in March 2020 (
see Related Summaries, below) reflects lessons learned since the start of the pandemic and focuses on what the International Federation of Red Cross and Red Crescent Societies (IFRC) is aiming to achieve over the coming year, including on building and maintaining trust in the vaccine.
Cvirus - UNICEF firma un acuerdo de suministro de la vacuna de Pfizer/BioNTech contra el coronavirus clarin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clarin.com Daily Mail and Mail on Sunday newspapers.
Victoria pauses all international arrivals from Saturday; Infected cleaner sees Melbourne airport become an exposure site; Victoria goes into five day lockdown to fight the contagious UK strain. Follow updates here.
Patent Capital in the Covid-19 Pandemic: Critical Intellectual Property Law
The current controversy around intellectual property rights has focused on the role of intellectual property in the current Covid-19 vaccine shortage. But the present situation should not be understood as a manifestation of an exceptional legal event. Rather, it is a reflection of the legal normal that has been in place for the last twenty-five years since the 1995 TRIPS Agreement that forms the legal transnational structure for intellectual property-driven knowledge capitalism.
Patent rights grant monopoly power to their holders – mostly multinational corporations. The problems that these transnational monopoly rights cause have been well-known: patents on medical inventions, in particular, have provided pharmaceutical corporations, as well as the more under the radar biotechnology companies, with the right to charge exorbitant prices, limit supply through exclusive licensing contracts, prohibit pa